DIA
Drug Information Association Logo

Special Opportunities for Patient Representatives

DIA 2013 49th Annual Meeting 

Do you represent a 501(c)(3) organization that serves constituents with major chronic diseases and/or rare/orphan diseases? Then you can’t afford to miss this opportunity to attend the DIA 2013 49th Annual Meeting.

DIA 2013 49th Annual Meeting connects all partners involved in bringing new therapies to patients. Historically, this enterprise has focused on drug development, but today those partners include a very diverse range of stakeholders from pharmaceutical, biotechnology, diagnostics and device companies, to regulatory agencies, scientific and academic communities, service payers and providers, and patient organizations. See for Yourself What Others are Saying about the DIA Annual Meeting...


As a biotech company representative, I am looking forward to attending the DIA Annual Meeting.  I am interested in working with the patient advocacy groups in order to better educate patients about clinical trials and make our studies more patient-friendly.   The DIA Annual Meeting Patient Advocate Fellowship Program provides a great opportunity to learn about the best practices and challenges that patient advocacy groups are facing in clinical trials.

Christine Dehner
Sr. Manager Clinical Trials, Seattle Genetics


Special Discount for Patient Advocates!

Special Rate
Representatives of patient organizations can attend the Annual Meeting for only $250 (a discount of $800 off the nonprofit rate). A one-year complimentary DIA e-membership is also included. Proof of 501(c)3 status required.

By attending the DIA Annual Meeting, you will have the opportunity to:

  • Develop, strengthen, and support patient collaborations and those of patients you represent with policy makers, health professionals, industry representatives, and academia
  • Increase your knowledge and understanding of patient groups about key issues central to patient-centered health care, biomedical research, and drug development, and take this wealth of information back to your constituency
  • Improve alliances between the patient groups you represent and other health care stakeholders
  • Stimulate cooperation, promote dialogue, and share best practices on both personal and organizational levels


Recommended Sessions for Patient Advocates

Tuesday

Leveraging In-Pharmacy Education to Improve Patient Comprehension and Access to Clinical Trials
Event Type: FORUM
Tracks: Track 01 - Clinical Operations

Development of a New Patient-reported Outcome (PRO) Measure for Depression: Progress and Results from the PRO Consortium
Event Type: FORUM
Tracks: Track 07 - Processes and Technologies for Clinical Research

Payer Collaborations with Pharma: Real World Evidence to Improve Patient Outcomes and Influence the Pipeline
Event Type: SESSION
Tracks: Track 13 - Health Economics and
Outcomes (HEO)/Comparative Effectiveness Research (CER)/Health Technology Assessment (HTA)

Social Media, Mobile Applications and Patient Support Programs: Challenges and Solutions for Handling Drug Safety Information
Event Type: SESSION
Tracks: Track 14 - Clinical Safety and Pharmacovigilance

Research Advances for Rare Diseases and Orphan Products
Event Type: SESSION
Tracks: Track 17 - Rare/Orphan Diseases

Optimizing Clinical Trial Feasibility by Collaborating with Investigators, Patient Advocacy Associations and Electronic Health Record Partners
Event Type: SESSION
Tracks: Track 01 - Clinical Operations

Patient-centered Predictive Modeling and Its Role in Creating a Learning Health System
Event Type: SESSION
Tracks: Track 13 - Health Economics and
Outcomes (HEO)/Comparative Effectiveness Research (CER)/Health Technology Assessment (HTA)

Is There a Recipe for Successful Implementation of Registries for Rare Diseases?
Event Type: SESSION
Tracks: Track 17 - Rare/Orphan Diseases

Bringing the Views of “Payer Regulators” into Product Development to Align Label Outcomes and Safety with Patient Access
Event Type: SESSION
Tracks: Track 08 - Regulatory Affairs and Submissions

Labeling and Patient Medical Information (PMI)
Event Type: SESSION
Tracks: Track 08 - Regulatory Affairs and Submissions

Development for Rare Disease Treatments
Event Type: SYMPOSIUM
Tracks: Track 17 - Rare/Orphan Diseases


Wednesday

Clinical Trial Design for Optimal Patient Recruitment and Retention
Event Type: SESSION
Tracks: Track 01 - Clinical Operations

Models for Genomic Research Success: How a Patient-Researcher Relationship Led to the Discovery of a Norepinephrine Transporter Deficiency and the Emerging Role of Crowd Sourcing in Rare Disease
Research
Event Type: SESSION
Tracks: Track 17 - Rare/Orphan Diseases

Driven by Data: More Effective Strategies to Reach Your Patient Recruitment Goals
Event Type: SYMPOSIUM
Tracks: Track 01 - Clinical Operations

Project Data Sphere: Clinical Trial Datasharing in Cancer to Accelerate Innovation and Enhance Patient Health
Event Type: FORUM
Tracks: Track 03 - Innovative Partnering
Models and Outsourcing Strategies

FDASIA Patient Provisions: One Year Later
Event Type: SESSION
Tracks: Track 08 - Regulatory Affairs and Submissions

Advancing Alzheimer's Innovation: Patient
Advocacy and Caregiver
Event Type: FORUM
Tracks: Track 08 - Regulatory Affairs and Submissions

Rising to the Challenge of Developing Novel Orphan Medicines for the Global Market
Event Type: SESSION
Tracks: Track 17 - Rare/Orphan Diseases

Innovative Ways of Working with Patients to Make Clinical Research More Productive, Less Costly and Less Burdensome for the Patient
Event Type: SYMPOSIUM
Tracks: Track 01 - Clinical Operations

Learnings from Safety Communications Across the Industry: Patients and EMA, REMS, and FDA, Physicians, and Medical Information Groups
Event Type: SYMPOSIUM
Tracks: Track 06 - Medical Communication, Medical Writing, and Medical Liaison

Clinical Trial Visit of the Future: Leveraging Emerging Technologies to Crack the Patient Recruitment Challenge
Event Type: WORKSHOP
Tracks: Track 07 - Processes and Technologies for Clinical Research

Developing a Patient Aid to Make Information about Treatment Benefits, Harms and Uncertainties Meaningful to Individual Patients and Enhance Their Decisions
Event Type: SESSION
Tracks: Track 14 - Clinical Safety and Pharmacovigilance

Ensuring Patient-centered Care: Partnering with Patient Advocacy
Event Type: SESSION
Tracks: Track 16 – Professional Development

Rescuing and Repurposing Drugs: Challenges and Opportunities
Event Type: FORUM
Tracks: Track 17 - Rare/Orphan Diseases

Thursday


The Not So Rare Challenge that Faces Rare Disease Development: Demonstrate Value
Event Type: SESSION
Tracks: Track 17 - Rare/Orphan Diseases

© 2014 DIA